OTLK Valuation

Outlook Therapeutics Inc

Add to Watchlist

Advanced Chart

0.851

-0.239(-21.927%)1D

Overview
Forecast
Valuation
Earnings

OTLK Relative Valuation

OTLK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OTLK is overvalued; if below, it's undervalued.

Historical Valuation

Outlook Therapeutics Inc (OTLK) is now in the Fair zone, suggesting that its current forward PS ratio of 1.74 is considered Fairly compared with the five-year average of -4.29. The fair price of Outlook Therapeutics Inc (OTLK) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.85

Fair

-0.88

Trailing

Forward

0.00

EV/EBITDA

Outlook Therapeutics Inc. (OTLK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.43

EV/EBIT

Outlook Therapeutics Inc. (OTLK) has a current EV/EBIT of -1.43. The 5-year average EV/EBIT is -4.04. The thresholds are as follows: Strongly Undervalued below -8.70, Undervalued between -8.70 and -6.37, Fairly Valued between -1.71 and -6.37, Overvalued between -1.71 and 0.62, and Strongly Overvalued above 0.62. The current Forward EV/EBIT of -1.43 falls within the Overvalued range.

1.74

Outlook Therapeutics Inc. (OTLK) has a current PS of 1.74. The 5-year average PS is 309.96. The thresholds are as follows: Strongly Undervalued below -621.85, Undervalued between -621.85 and -155.95, Fairly Valued between 775.87 and -155.95, Overvalued between 775.87 and 1241.77, and Strongly Overvalued above 1241.77. The current Forward PS of 1.74 falls within the Historic Trend Line -Fairly Valued range.

-0.75

P/OCF

Outlook Therapeutics Inc. (OTLK) has a current P/OCF of -0.75. The 5-year average P/OCF is -4.93. The thresholds are as follows: Strongly Undervalued below -12.32, Undervalued between -12.32 and -8.62, Fairly Valued between -1.23 and -8.62, Overvalued between -1.23 and 2.47, and Strongly Overvalued above 2.47. The current Forward P/OCF of -0.75 falls within the Overvalued range.

0.00

P/FCF

Outlook Therapeutics Inc. (OTLK) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.90. The thresholds are as follows: Strongly Undervalued below -7.39, Undervalued between -7.39 and -4.64, Fairly Valued between 0.84 and -4.64, Overvalued between 0.84 and 3.59, and Strongly Overvalued above 3.59. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Outlook Therapeutics Inc (OTLK) has a current Price-to-Book (P/B) ratio of -1.00. Compared to its 3-year average P/B ratio of 0.82 , the current P/B ratio is approximately -220.71% higher. Relative to its 5-year average P/B ratio of 9.35, the current P/B ratio is about -110.64% higher. Outlook Therapeutics Inc (OTLK) has a Forward Free Cash Flow (FCF) yield of approximately -149.26%. Compared to its 3-year average FCF yield of -52.66%, the current FCF yield is approximately 183.45% lower. Relative to its 5-year average FCF yield of -38.39% , the current FCF yield is about 288.79% lower.

-1.00

P/B

Median3y

0.82

Median5y

9.35

-149.26

FCF Yield

Median3y

-52.66

Median5y

-38.39

Competitors Valuation Multiple

The average P/S ratio for OTLK's competitors is 6.27, providing a benchmark for relative valuation. Outlook Therapeutics Inc Corp (OTLK) exhibits a P/S ratio of 1.74, which is -72.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

OTLK.O

Outlook Therapeutics Inc

Onkure Therapeutics Inc

Loss

37.21M

RLMD.O

Relmada Therapeutics Inc

Loss

37.17M

XLO.O

Xilio Therapeutics Inc

CASI Pharmaceuticals Inc

Performance Decomposition

Market capitalization of OTLK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of OTLK in the past 1 year is driven by Unknown.